|
Shares of Unichem Laboratories surged 12.64% in the past three sessions.
So far in 2021, the stock has fallen 1.27% while the benchmark Sensex has added 27.43% during the same period.
On the technical front, the stock's RSI (relative strength index) stood at 62.14. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30.
The stock was trading above its 50-day, 100-day and 200-day simple moving average (SMA) placed at 242.28, 227.41 and 222.86, respectively.
On a consolidated basis, Unichem Laboratories reported net loss of Rs 12.82 crore in Q2 September 2021 as against net profit of Rs 8.74 crore in Q2 September 2020. Net sales declined 8.46% to Rs 290.66 crore in Q2 September 2021 over Q2 September 2020.
Unichem Laboratories is a pharmaceutical company. It has products in therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.
|